Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by ENEMENEMYNEMOon Apr 29, 2022 11:34am
162 Views
Post# 34642478

RE:RE:It's holding pretty steady Walter. Waiting to buy cheaper

RE:RE:It's holding pretty steady Walter. Waiting to buy cheaper

LETS GO HEMOSTEMIX!!!!

Anyone know if they obtained the keys to the data yet or just confirmed that it wasnt corrupted? It might take a few months to analyze the data and write up a paper. 


If this works the upside really is huge as a single use but also potentially for co-therapy for all the other stem-cell companies out there attempting to grow various cell lines.... they all need a vascular base and HEMO's got it!!!!! To hell with "pouches"!

The CEO compared Hem to MyoKardia...13b buyout.  At first I though it was a foolish comparison but if you look at what MyoKardia has (drug for hypertrophic cardiomyopathy, just approved yesterday!), thats got nothin on the potential for HEMO's product!

Bristol paid $225/share for MyoKardia before Phaselll results!

im goin' boat shopping soon!!!!  

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse